White Paper Report

Timestamp: 2026-03-12 15:23:00

BIOX Whitepaper 2.0

ungültige Fassung


			..
	White paper for crypto-assets other than asset-referenced tokens or e-money tokens

	Digital Token Identifier:	5HL762TWK
	Offeror or person seeking admission to trading:	52990050KC7YUM8VD941 - Biogena GmbH & Co KG
	Type of submission:	Modify

Table of content
General information
SUMMARY
Part A - Information about offeror or person seeking admission to trading
Part B - Information about issuer, if different from offeror or person seeking admission to trading
Part C - Information about the operator of the trading platform in cases where it draws up the crypto-asset white paper and information about other persons drawing the crypto-asset white paper pursuant to Article 6(1), second subparagraph, of Regulation (EU) 2023/1114
Part D - Information about other token project
Part E - Information about offer to public of other tokens or their admission to trading
Part F - Information about other tokens
Part G - Information on rights and obligations attached to other tokens
Part H – Information on underlying technology
Part I - Information on risks
Part J - Information on the sustainability indicators in relation to adverse impact on the climate and other environment-related adverse impacts




[Table 2] Template for white papers for crypto-assets other than asset-referenced tokens or e-money tokens

Template for white papers for crypto-assets other than asset-referenced tokens or e-money tokens [abstract]
General information
00 Table of content	boolean true	true
01 Date of notification	date	2026-03-02
02 Statement in accordance with Article 6(3) of Regulation (EU) 2023/1114	boolean true	This crypto-asset white paper has not been approved by any competent authority in any Member State of the European Union. The offeror of the crypto-asset is solely responsible for the content of this crypto-asset white paper.
03 Compliance statement in accordance with Article 6(6) of Regulation (EU) 2023/1114	boolean true	This crypto-asset white paper complies with Title II of Regulation (EU) 2023/1114 of the European Parliament and of the Council and, to the best of the knowledge of the management body, the information presented in the crypto-asset white paper is fair, clear and not misleading and the crypto-asset white paper makes no omission likely to affect its import.
04 Statement in accordance with Article 6(5), points (a), (b), (c), of Regulation (EU) 2023/1114	boolean true	The crypto-asset referred to in this crypto-asset white paper may lose its value in part or in full, may not always be transferable and may not be liquid
05 Statement in accordance with Article 6(5), point (d), of Regulation (EU) 2023/1114	boolean true	The utility token referred to in this white paper may not be exchangeable against the good or service promised in this white paper, especially in the case of a failure or discontinuation of the crypto-asset project.
06 Statement in accordance with Article 6(5), points (e) and (f), of Regulation (EU) 2023/1114	boolean true	The crypto-asset referred to in this white paper is not covered by the investor compensation schemes under Directive 97/9/EC of the European Parliament and of the Council or the deposit guarantee schemes under Directive 2014/49/EU of the European Parliament and of the Council.
SUMMARY
07 Warning in accordance with Article 6(7), second subparagraph, of Regulation (EU) 2023/1114	boolean true	Warning This summary should be read as an introduction to the crypto-asset white paper. The prospective holder should base any decision to purchase this crypto –asset on the content of the crypto-asset white paper as a whole and not on the summary alone. The offer to the public of this crypto-asset does not constitute an offer or solicitation to purchase financial instruments and any such offer or solicitation can be made only by means of a prospectus or other offer documents pursuant to the applicable national law. This crypto-asset white paper does not constitute a prospectus as referred to in Regulation (EU) 2017/1129 of the European Parliament and of the Council or any other offer document pursuant to Union or national law.
08 Characteristics of the crypto-asset	textBlock	BIOGENA EXPERIENCE TOKEN ("BIOX") has a maximum subscription goal of 35,000,000 token, it is, however, not limited to this amount but only limited by the issuance period (see E.22). BIOX is operated with a protocol-based emission model, allowing for additional token issuance to support network growth and locking-up the token. The token exists as BIOX and is an ERC-20 token (second layer polygon) minted on Ethereum. The token has the following functionality (upon implementation of this functionality (D.8)): • locking-up / unlocking. BIOX can be purchased via www.biogena.com/biox. BIOX purchasers, if qualified as consumers, have a 14 days withdrawal period. The minimum purchase amount is one (1) BIOX. The issuance price is determined in Euro with a fixed purchase price of (1) one Euro per BIOX. After locking-up BIOX in a required amount (minimum each of 3,000, 30,000, 100,000 or 200,000 BIOX) the BIOX holder has access to several rebates (as defined in D.7) in particular on Biogena products and services. When locking-up BIOX a lock-up period of 12 months applies. The holder can unlock during this period, effective by the expiry of the lockup period. Upon 11 months of locking-up the BIOX holder will get a notification of his right to unlock. If the BIOX holder does not unlock during the ongoing lock-up period of 12 months a new lock-up period (of 12 months) starts automatically after expiry of the previous lockup period. If during an ongoing lock-up period the holder decides to lock-up more BIOX in the amount to reach a new level (3,000, 30,000, 100,000 or 200,000 BIOX), the new lock-up period applies to all BIOX that have been newly locked up, as well as to the BIOX that were already locked-up prior to the new lock-up period. BIOX is not mandatory for using the Biogena platform, all products and services remain accessible under the standard prices. BIOX is not intended to be exchanged for goods and services or to be a currency, whatsoever. At a later date trading of BIOX on reputable trading platforms shall be possible. Rebates and other benefits will be granted for 40 years, calculated beginning at the regular end of the offer phase, and subject to this Whitepaper. Transfer of token may require payment of gas fees by the initator of the transaction. Beyond these utilities, BIOX does not convey claims and rights against the offeror save for ownership rights over the tokens themselves and rebate rights contingent upon locking-up and the amount of token locked-up. BIOX does not grant any governance rights, whatsoever, over the offeror or any of its affiliates. 10% of BIOX sale proceeds will be donated to a welfare project of the issuer, the BIOGENA ONE WORLD FOUNDATION.
09 Further information about utility tokens	textBlock	BIOX as a utility token shall give access to rebates on all Biogena products and services and grant further benefits, depending on the amount of BIOX held and locked-up. The rebates are the following and require a certain number of locked-up BIOX starting by at least 3,000: • rebates of 30% of the purchase price (regular price and promotional or discounted price) on all Biogena products, biohacking applications and wellbeing checks and subscriptions for every single purchase for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and 3,000 BIOX are being locked-up. • participation of the BIOX holder in raffles (Verlosungen) of tickets for at least 300 different cultural and sporting events. The raffles shall take place once a year and shall contain each of about 100 tickets for the "Jedermann"-Festival, Kitzbühel Streif ski event and Skybox VIP invitations for the Red Bull Arena in Salzburg. Further events shall be made available, such as specific Health Days and a yearly dinner with the Founder and Management Team. The raffles shall be conducted for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and 3,000 BIOX are being locked-up. • one free subscription to Biogena ONE, an All-in-ONE green drink, plus ADD+ ONE Omega-3 Support for a maximum period of 40 years (monthly delivery), calculated beginning at the regular end of the offer phase, if and as long as 30,000 or more BIOX are being held and 30,000 are being locked-up. • initial offer exclusively for token holders and discounts to real estate investments in up to 25 'Welcome to Yourself Resorts (WTY)' planned worldwide, depending on the amount of BIOX held and locked-up as follows: (i) initial offer exclusively for token holders and 10% discount if 30,000 to 99,999 are being held and thereof 30,000 BIOX are being locked-up, (ii) initial offer exclusively for token holders and 20% discount if 100,000 to 199,999 are being held and thereof 100,000 BIOX are being locked-up,, (iii) initial offer exclusively for token holders and 25% discount if 200,000 or more BIOX are being held and thereof 200,000 BIOX are being locked-up. For the avoidance of any doubt, the offeror (i) envisages building 'Welcome to Yourself Resorts (WTY)', but shall have no legal obligation to do so and (ii) has not yet decided on the detailed structure of such respective investment. In case the offeror offers an investment opportunity in 'Welcome to Yourself Resorts (WTY)', such offer shall be offered to the holders of BIOX, having held and locked-up 30,000, 100,000 or 200,000 BIOX or more, at least for a period of fourteen (14) days before such investment is offered to the public. • one Biogena LONGEVITY Stick monthly subscription for 40 years, calculated beginning at the regular end of the offer phase, if 100,000 or more BIOX are being held and thereof 100,000 or 200,000 BIOX are being locked-up. The Biogena LONGEVITY Stick is a new supplement and micronutrient product aiming to help slow aging. • Limited membership in the 3 BIOX Circles (solely consisting of the members of the ONYX Circle, PLATIN Circle, BERNSTEIN Circle, total maximum of 80 people) combined with a unique piece of jewelry limited in number and crafted by an artist as follows: (i) ONYX Circle Membership, limited to 50 members plus one BIOX Onyx ring, if 30,000 to 99,999, are being held and thereof 30,000 BIOX are being locked-up, (ii) PLATIN Circle Membership, limited to 20 members plus one BIOX Platin ring, if 100,000 to 199,999 are being held and thereof 100,000 BIOX are being locked-up,and (iii) BERNSTEIN Circle Membership, limited to 10 members plus one BIOX Bernstein ring, if 200,000 or more BIOX are being held and thereof 200,000 BIOX are being locked-up. (These rebates on products and services as well as other benefits are in the following referred to as the "rebate"). Further, to ensure responsible and sustainable use of BIOX and its granted rebates, the following fair use principle applies to all BIOX holders: 1. Personal use BIOX rebates are intended exclusively for the personal use of the BIOX holder and for personal use within the immediate family. The transfer, sale or commercial use of the rebates is not permitted. An exception to this shall apply within the framework of existing business partner relationships with doctors/therapists, where a use within the practice is considered fair use – but not a resale outside of the practice. 2. Reasonable purchasing frequency Rebates may be used within the scope of a normal and reasonable purchasing frequency. The following applies as a guideline: • a maximum of 6 rebated orders per calendar month. Higher frequencies are possible, but must be in a reasonable proportion to personal consumption and must not reflect resale activities. 3. Quantity limits to prevent abuse BIOX rebates may not be used for: • the purchase of unusually large quantities (e.g. stock purchases for resale), • orders that objectively suggest commercial or systematic use. 4. Protection against automated or technical abuse Any form of automated ordering, price manipulation or circumvention of the rules of use will result in the suspension or termination of the rebate entitlement. 5. Monitoring & transparency The issuer is entitled to: • randomly check the use of rebates, • temporarily block them in case of suspected abuse, • permanently withdraw the rebates entitlement in clear cases. The BIOX holder will be informed transparently about all measures. 6. Fairness principle It shall create a system that: • offers all BIOX holders a fair advantage, • does not create any distortion of competition, • protects the long-term value of the BIOX ecosystem. The issuer undertakes to apply this principle in a customer-friendly, proportionate and transparent manner.
10 Key information about the offer to the public or admission to trading	textBlock	The issuance of BIOX shall lead to further growth of the company and promote customer loyalty. Offering Phase: • BIOX shall be offered from December 16th 2025 until June 17h 2026. The offeror is entitled to shorten or terminate the offering phase at any time. The purchase price will be 1 Euro per BIOX at all times during the offering phase. Following the initial purchase during the offering phase: • Following the initial purchase a waiting period of 14 days will apply. During this waiting period the BIOX holder can withdraw from the purchase of BIOX (see E.26). BIOX will be transferred to the users wallet, which is a custodial wallet; • Following the initial purchase and the waiting period BIOX can be locked-up or unlock by the BIOX holder;; • Following the initial purchase and the waiting period BIOX can be transferred from the custodial wallet of his/her Biogena account to a wallet other than the initial custodial wallet subject to achievement of the milestone " Transferability functionality" (see D.8). • It is envisaged to list BIOX on reputable trading platforms.
Part A - Information about offeror or person seeking admission to trading
A.1 Name	text	Biogena GmbH & Co KG
A.2 Legal form	text	private limited partnership (Gesellschaft mit beschränkter Haftung & Compagnie Kommanditgesellschaft)
A.3 Registered address
Registered addess	text	Strubergasse 24, 5020 Salzburg, Austria
Country	enumeration	Austria
Sub-division	text	non
A.4 Head office
Head office	text	Strubergasse 24, 5020 Salzburg, Austria
Country	enumeration	Austria
Sub-division	text	non
A.5 Registration date	date	2020-01-11
A.6 Legal entity identifier	LEI	52990050KC7YUM8VD941
A.7 Another identifier required pursuant to applicable national law	text	525900 h
A.8 Contact telephone number	text	0662 23 11 11
A.9 E-mail address	text	info@biogena.com
A.10 Response time (days)	integer	7
A.11 Parent company	text	Biogena Naturprodukte GmbH as general partner and Biogena Group Invest GmbH & Co KG as limited partner
A.12 Members of the management body
Member #1	id	1
Identity	text	Dr. Albert Schmidbauer
Business address	text	Strubergasse 24, 5020 Salzburg
Function	text	Managing Director of the unlimited liable shareholder (Biogena Group Invest GmbH & Co KG) and managing director of the limited liable shareholder (Biogena Naturprodukte GmbH) of the company
Member #2	id	2
Identity	text	Stefan Klinglmair
Business address	text	Strubergasse 24, 5020 Salzburg
Function	text	Managing Director of the unlimited liable shareholder (Biogena Group Invest GmbH & Co KG) and managing director of the limited liable shareholder (Biogena Naturprodukte GmbH) of the company
Member #3	id	3
Identity	text	Mag. Martin Gratzer
Business address	text	Strubergasse 24, 5020 Salzburg
Function	text	Managing Director of the unlimited liable shareholder (Biogena Group Invest GmbH & Co KG) and managing director of the limited liable shareholder (Biogena Naturprodukte GmbH) of the company
Member #4	id	4
Identity	text	Margit Loidl
Business address	text	Strubergasse 24, 5020 Salzburg
Function	text	Managing Director of the unlimited liable shareholder (Biogena Group Invest GmbH & Co KG) and managing director of the limited liable shareholder (Biogena Naturprodukte GmbH) of the company
Member #5	id	5
Identity	text	Julia Marisa Hagenauer, MA
Business address	text	Strubergasse 24, 5020 Salzburg
Function	text	Managing Director of the unlimited liable shareholder (Biogena Group Invest GmbH & Co KG) and managing director of the limited liable shareholder (Biogena Naturprodukte GmbH) of the company
Member #6	id	6
Identity	text	Julia Hoffmann, MSc
Business address	text	Strubergasse 24, 5020 Salzburg
Function	text	Managing Director of the unlimited liable shareholder (Biogena Group Invest GmbH & Co KG) and managing director of the limited liable shareholder (Biogena Naturprodukte GmbH) of the company
A.13 Business activity	textBlock	Biogena Naturprodukte GmbH purpose is the production and sale of natural products as well as health products. Biogena Group Invest GmbH & Co KG purpose is the operation of a holding company including the acquisition, management, and sale of participations in domestic and foreign companies of all kinds. It may finance other companies.
A.14 Parent company business activity	textBlock	Biogena Naturprodukte GmbH purpose is the production and sale of natural products as well as health products. Biogena Group Invest GmbH & Co KG purpose is the operation of a holding company including the acquisition, management, and sale of participations in domestic and foreign companies of all kinds. It may finance other companies.
A.15 Newly established	boolean	false
A.16 Financial condition for the past three years	textBlock	In the past three years, the offeror further fostered its market leading position in the Austrian micronutrition and longevity market. Number of clients: The offeror has experienced a constant growth of clients from ca. 570,000 in 2022 to ca 600,000 in 2023 to ca. 600,000 in 2024 and to ca 900,000 in Q3/2025. Total assets: The total assets of the offeror increased from EUR 77,283,079.89 thousand in 2022 to EUR 94,065,082.30 thousand in 2023 and to EUR 109,581,718.27 thousand in 2024. Income and loss statement: The financial statements for the past three years have been duly prepared and submitted on time to the Austrian commercial court register. The net profit of the offeror was EUR 5,508,880.81 in 2022, EUR 4,627,878.74 in 2023 and EUR 4,258,759.24 in 2024. Due to increase in personnel expenses the profits have decreased in the past three years. Further higher energy costs as well as raw materials lead to a decrease of the net profits. Funding sources: The offeror's funding sources, as reflected in its financial statements, primarily include debt investments, such as bonds, banks and retained earnings.
A.17 Financial condition since registration	textBlock	Not applicable, see A.16
Part B - Information about issuer, if different from offeror or person seeking admission to trading
B.1 Issuer different from offerror or person seeking admission to trading	boolean	false
B.2 Name	N/A		.
B.3 Legal form	N/A		.
B.4 Registered address
Registered addess	N/A		.
Country	N/A		.
Sub-division	N/A		.
B.5 Head office
Head office	N/A		.
Country	N/A		.
Sub-division	N/A		.
B.6 Registration date	N/A		.
B.7 Legal entity identifier	N/A		.
B.8 Another identifier required pursuant to applicable national law	N/A		.
B.9 Parent company	N/A		.
B.10 Members of the management body
Member #1	N/A		.
Identity	N/A		.
Business address	N/A		.
Function	N/A		.
B.11 Business activity	N/A		.
B.12 Parent company business activity	N/A		.
Part C - Information about the operator of the trading platform in cases where it draws up the crypto-asset white paper and information about other persons drawing the crypto-asset white paper pursuant to Article 6(1), second subparagraph, of Regulation (EU) 2023/1114
C.1 Name	N/A		.
C.2 Legal form	N/A		.
C.3 Registered address
Registered address	N/A		.
Country	N/A		.
Sub-division	N/A		.
C.4 Head office
Head office	N/A		.
Country	N/A		.
Sub-division	N/A		.
C.5 Registration date	N/A		.
C.6 Legal entity identifier	N/A		.
C.7 Another identifier required pursuant to applicable national law	N/A		.
C.8 Parent company	N/A		.
C.9 Reason for crypto-asset white paper preparation	N/A		.
C.10 Members of the management body
Member #1	N/A		.
Identity	N/A		.
Business address	N/A		.
Function	N/A		.
C.11 Operator business activity	N/A		.
C.12 Parent company business activity	N/A		.
C.13 Other persons drawing up the crypto-asset white paper according to Article 6(1), second subparagraph, of Regulation (EU) 2023/1114	N/A		.
C.14 Reason for drawing the white paper by persons referred to in Article 6(1), second subparagraph, of Regulation (EU) 2023/1114	N/A		.
Part D - Information about other token project
D.1 Crypto-asset project name	text	Biogena Experience Token (BIOX)
D.2 Crypto-asset name	text	Biogena Experience Token (BIOX)
D.3 Abbreviation	text	BIOX
D.4 Crypto-asset project description	textBlock	BIOX constitutes a token project to grant customers the possibility of holding and locking-up BIOX to get access to rebates on services and goods provided by Biogena, as well as a common welfare part, as 10% of the token sale proceeds will be given to a welfare project of the issuer, the BIOGENA ONE WORLD FOUNDATION. There is no initial total amount of token, depending on the demand during the offer phase, token will be minted on the Ethereum standard (ERC-20). BIOX is offered to persons who are based in Germany and Austria. An automated transferability functionality shall be implemented as a milestone to be achieved in 2026. BIOX purchased by the users will be transferred to the users custodial wallet. Automated Transferability to other wallets than the custodial wallet will be possible upon achievement of the milestone "Transferability functionality of BIOX" (see D.8). Until achievement of this milestone, a manual transfer conducted by Tangany GmbH of BIOX to other wallets than the custodial wallet is possible when requested by the holder. Primary Objective: - encouraging the regular purchase of Biogena products and services as well as promotion of longterm customer loyalty as well as providing funds for a welfare project of the issuer, the BIOGENA ONE WORLD FOUNDATION.
D.5 Details of all natural or legal persons involved in implementation of crypto-asset project
Person #1	id	1
Type of person	enumeration	Other person involved in implementation
Name of person	text	NEVO Group GmbH
Business address of person	text	Murtalstraße 641, St. Michael im Lungau 5582, Austria
Domicile of company	enumeration	Germany
Person #2	id	2
Type of person	enumeration	Development team
Name of person	text	tokenforge GmbH
Business address of person	text	Hohe Bleichen 8, 20354 Hamburg
Domicile of company	enumeration	Germany
Person #3	id	3
Type of person	enumeration	Other person involved in implementation
Name of person	text	CONCEDUS GmbH
Business address of person	text	Ostendstraße 100, 90482 Nuernberg
Domicile of company	enumeration	Germany
Person #4	id	4
Type of person	enumeration	Development team
Name of person	text	Hilarion 5 IT Solutions GmbH
Business address of person	text	Schneiderweg 2, 5165 Berndorf bei Salzburg
Domicile of company	enumeration	Austria
Person #5	id	5
Type of person	enumeration	Crypto-asset service provider
Name of person	text	Tangany GmbH
Business address of person	text	Brienner Straße 53, 80333 Munich
Domicile of company	enumeration	Germany
D.6 Utility token classification	boolean	true
D.7 Key features of goods or services for utility token projects	text	BIOX, as a utility token, shall give access to rebates on all Biogena products and services and grant further benefits, depending on the amount of BIOX held and locked-up. • rebates of 30% of the purchase price (regular price and promotional or discounted price) on all Biogena products, biohacking applications and wellbeing checks and subscriptions for every single purchase for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and thereof 3,000 BIOX are being locked-up. • participation of the BIOX holder in raffles (Verlosungen) for at least 300 different cultural and sporting events. The raffles shall take place once a year and shall contain each of about 100 tickets for the "Jedermann"-Festival, Kitzbühel Streif ski event and Skybox VIP invitations for the Red Bull Arena in Salzburg. Further events shall be made available, such as specific Health Days and a yearly dinner with the Founder and Management Team. The raffles shall be conducted for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and thereof 3,000 BIOX are being locked-up. • one free subscription to Biogena ONE, an All-in-ONE green drink, plus ADD+ ONE Omega-3 Support for a maximum period of 40 years (monthly delivery), calculated beginning at the regular end of the offer phase, if and as long as 30,000 or more BIOX are being held and thereof 30,000 BIOX are being locked-up. • initial offer exclusively for token holders and discounts to real estate investments in up to 25 'Welcome to Yourself Resorts (WTY)' planned worldwide, depending on the amount of BIOX held and locked-up as follows: (i) initial offer exclusively for token holders and 10% discount if 30,000 to 99,999 are being held and thereof 30,000 BIOX are being locked-up, (ii) initial offer exclusively for token holders and 20% discount if 100,000 to 199,999 are being held and thereof 100,000 BIOX are being locked-up, (iii) initial offer exclusively for token holders and 25% discount if 200,000 or more BIOX are being held and thereof 200,000 BIOX are being locked-up. For the avoidance of any doubt, the offeror (i) envisages building 'Welcome to Yourself Resorts (WTY)', but shall have no legal obligation to do so and (ii) has not yet decided on the detailed structure of such respective investment. In case the offeror offers an investment opportunity in 'Welcome to Yourself Resorts (WTY)', such offer shall be offered to the holders of BIOX, having held and locked-up 30,000, 100,000 or 200,000 BIOX, at least for a period of fourteen (14) days before such investment is offered to the public. • one Biogena LONGEVITY Stick monthly subscription for 40 years, calculated beginning at the regular end of the offer phase, if 100,000 or more BIOX are being held and thereof 100,000 or 200,000 BIOX are being locked-up. The Biogena LONGEVITY Stick is a new supplement and micronutrient product aiming to help slow aging. • Limited membership in the 3 BIOX Circles (solely consisting of the members of the ONYX Circle, PLATIN Circle, BERNSTEIN Circle, total maximum of 80 people) combined with a unique piece of jewelry limited in number and crafted by an artist as follows: (i) ONYX Circle Membership, limited to 50 members plus one BIOX Onyx ring, if 30,000 to 99,999 are being held and thereof 30,000 BIOX are being locked-up, (ii) PLATIN Circle Membership, limited to 20 members plus one BIOX Platin ring, if 100,000 to 199,999 are being held and thereof 100,000 BIOX are being locked-up, (iii) BERNSTEIN Circle Membership, limited to 10 members plus one BIOX Bernstein ring, if 200,000 or more BIOX are being held and thereof 200,000 BIOX are being locked-up. (These rebates on products and services as well as other benefits are in the following referred to as the "rebate"). By locking-up BIOX a lock-up period of 12 months will apply. During that time, transfer of BIOX as well as unlocking BIOX shall not be possible. There are no other restrictions on transferability of BIOX. Each transfer requires gas fees. The automated transfer of BIOX to other wallets of a BIOX holder is possible upon its implementation (D.8), until achieving this milestone a manual transfer is possible and provides by Tangany GmbH. The transfer has to be requested by the holder. To lock or unlock BIOX, the token must be deposited in the custodial wallet of the user provided by Tangany GmbH. This wallet must be accessed via the BIOX holders account www.biogena.com/biox. Locking-up on any other wallet is not possible. Locking-up does not mean that the tokens are transferred to another party, a wallet or a contract. The token shall remain in the economic sphere of the holder on the custodial wallet of the user, but shall be locked-up for the certain period of time. At the time of drafting this whitepaper 2.0 (2nd of February 2026) there is no possibility of trading BIOX on trading platforms. It is envisaged that further possibilities of trading BIOX on reputable trading platforms shall be made available on www.biogena.com/biox.
D.8 Plans for the token
Description of past milestones	textBlock	The functionality of a custodial wallet has been implemented and made available to each BIOX holder. Further, a manual transferability functionality has been implemented. By request each BIOX holder can demand a transfer of his/her BIOX to other wallets then the custodial wallet provided by the offeror. The transfer is conducted manually by Tangany GmbH.
Description of future milestones	textBlock	Key Milestones: Automated Transferability functionality (Ongoing, estimated 2026): • As of the publication date (F.10) the automated transferability functionality of BIOX is not yet available. The offeror envisages to accomplish this functionality as soon as possible. In the meantime, BIOX can be transferred manually by Tangany GmbH to any other wallet by individual request of the individual holder. Admission to trading and expansion of exchange Listings (Ongoing 2026): • Following the end of the (regular or shortened) offering phase BIOX is envisaged to be admitted to trading on one or several selected centralised exchanges. This admission process is at the discretion of the offeror and involves meeting their respective listing requirements. The costs involved for the listing of BIOX on a trading platform or exchange will be borne by the offeror. For the avoidance of any doubt, the investor shall bear its own costs involved with the trading on a platform or exchange. • Listing on further major centralised exchanges to enhance liquidity and global access.
D.9 Resource allocation	text	All necessary resources for the implementation of the project are secured.
D.10 Planned use of collected funds or other tokens	text	The net proceeds generated from the issuance of the Biogena Experience Token will be used exclusively for the further development and expansion of the Biogena ecosystem, as well as for charitable and research-related purposes, as set forth below as part of the business areas (Geschäftszweige) of the offeror and its group companies. The planned use of funds is broken down as follows (calculated based on 35,000,000 BIOX being sold): • 30% will be invested in the further development of the customer-centric IT and communications infrastructure of the Biogena ecosystem. The aim is to improve the digital customer experience, in particular by optimising personalisation, service quality, data integration, security and user-friendliness within the Biogena customer portal, the Biogena app and the online and store systems; • 30% will be invested in the construction of the first 'Welcome to Yourself Resorts'. These locations will serve as practical implementations of the Biogena wellbeing concept, health prevention and the combination of relaxation, diagnostics and lifestyle. The resorts will be established as model locations for the Biogena health ecosystem; • 30% are dedicated to product development, research and diagnostics. The focus is on scientifically based innovation projects in the areas of osteoporosis, silent inflammation, stress management and diabetes prevention, as well as on the expansion of tele-medical consulting services and diagnostic systems (e.g. Biogena Wellbeing Check). The aim is to continuously improve the scientific basis and applicability of Biogena health solutions; • 10% of the net proceeds will be donated to the BIOGENA ONE WORLD FOUNDATION – Stiftung für Gesundheit, Klimaschutz & Umweltschutz sowie Fairness & Gerechtigkeit a charitable foundation currently being established by the offeror). The funds will be used to support initiatives aimed at protecting nature and the environment, particularly through CO2 sequestration, the promotion of biodiversity and marine conservation, as well as children's rights and equal opportunities by supporting education, nutrition, sports and exercise programmes, the provision of clean drinking water supplies, and more. Further, projects which are CO2 relevant and supported by the BIOGENA ONE WORLD FOUNDATION should be included in the so called Biogena Climate Positive Plus-Strategy, a self-commitment of the issuer to reduce CO2.
Part E - Information about offer to public of other tokens or their admission to trading
E.1 Public offering or admission to trading	enumeration	Offer to public
E.2 Reasons for public offer or admission to trading	textBlock	The public offering allows existing and new Biogena customers to acquire BIOX easily and make use of the benefits granted by locking-up BIOX. In general, the public offering aims to reach a broad distribution of the token as well as strengthening the customers loyalty to Biogena.
E.3 Fundraising target
Target expressed in currency	monetary	35000000,00	EUR
Target expressed in units	decimal	35000000,00
Target expressed in digital token identifier	text
E.4 Minimum subscription goals
Goals expressed in currency	monetary	1,00	EUR
Goals expressed in units	decimal	1,00
Goals expressed in digital token identifier	text
E.5 Maximum subscription goals
Goasl expressed in currency	monetary	35000000,00	EUR
Goals expressed in units	decimal	35000000,00
Goals expressed in digital token identifier	text
E.6 Oversubscription acceptance	boolean	true
E.7 Oversubscription allocation	text	Every additional subscription will be accepted under the same requirements.
Issue price details
E.8 Issue price	decimal	1,00
E.9 Official currency determining issue price	enumeration	Euro
E.9 Any other tokens determining issue price	text
E.10 Subscription fee
Fee expressed in currency	monetary	00,00	EUR
Fee expressed in units	decimal	0,0000
Fee expressed in digital token identifier	text	Not applicable.
E.11 Offer price determination method	text	The offer price is EUR 1 per 1 BIOX. The offer price is an unchangeable purchase price.
E.12 Total number of offered or traded other tokens	integer
E.13 Targeted holders	enumeration	All types of investors
E.14 Holder restrictions	text	When locking-up BIOX in the respective amount (09, D.7), a lock-up period of 12 months applies. The holder can unlock during this period, effective by the expiry of the lockup period. Upon 11 months of locking-up the BIOX holder will get a notification of his right to unlock. If the BIOX holder does not unlock during the ongoing lockup period (of 12 months) a new lockup period (of 12 months) starts automatically after expiry of the previous lockup period. In case the holder holds more BIOX than the amount locked-up (3,000, 30,000, 100,000 or 200,000), the remaining amount of BIOX is not locked-up, if the total amount of BIOX would not achieve the next higher level, but remains in the holder's wallet. The remaining amount of BIOX is transferable by individual request of the BIOX holder. After receival of the request, Tangany GmbH conducts the manual transfer of BIOX to other wallets then the custodial wallet. After the achievement of the milestone "automated transferability functionality"(D.8) the remaining amount of BIOX will be transferable for the holder. Further, to ensure responsible and sustainable use of BIOX and its granted rebates, the following fair use principle applies to all BIOX holders: 1. Personal use BIOX rebates are intended exclusively for the personal use of the BIOX holder and for personal use within the immediate family. The transfer, sale or commercial use of the rebates is not permitted. An exception to this shall apply within the framework of existing business partner relationships with doctors/therapists, where a use within the practice is considered fair use – but not a resale outside of the practice. 2. Reasonable purchasing frequency Rebates may be used within the scope of a normal and reasonable purchasing frequency. The following applies as a guideline: • a maximum of 6 rebated orders per calendar month. Higher frequencies are possible, but must be in a reasonable proportion to personal consumption and must not reflect resale activities. 3. Quantity limits to prevent abuse BIOX rebates may not be used for: • the purchase of unusually large quantities (e.g. stock purchases for resale), • orders that objectively suggest commercial or systematic use. 4. Protection against automated or technical abuse Any form of automated ordering, price manipulation or circumvention of the rules of use will result in the suspension or termination of the rebate entitlement. 5. Monitoring & transparency The issuer is entitled to: • randomly check the use of rebates, • temporarily block them in case of suspected abuse, • permanently withdraw the rebates entitlement in clear cases. The BIOX holder will be informed transparently about all measures. 6. Fairness principle It shall create a system that: • offers all BIOX holders a fair advantage, • does not create any distortion of competition, • protects the long-term value of the BIOX ecosystem. The issuer undertakes to apply this principle in a customer-friendly, proportionate and transparent manner. Locking-up or unlocking can only be initiated via www.biogena.com/biox. The aggregate amount of token locked-up has to correspond to the respective amount required for each level (see 09, D.7), therefore 3,000, 30,000, 100,000 or 200,000 BIOX can be locked-up, a different amount of BIOX cannot be locked-up. The amount of BIOX held by the holder is subject to their discretion, and can exceed the amount of locked-up BIOX. Besides the restriction during locking-up periods, no holder restrictions shall apply beyond legal prohibitions. Therefore, the sale is prohibited to potential purchasers who are prohibited from participation due to applicable regulations and legal requirements. Each transfer requires payment of gas fees. The gas fees for the initial transfer of BIOX will be borne by the issuer. A gas fee for a transfer from the custodial wallet to a third party wallet will be borne by the issuer until 16.12.2028. Other fees and costs for locking-up or unlocking as well as trading of BIOX on centralised exchanges, if admission is granted following the initial transfer as well as initial locking-up shall be borne by the holder.
E.15 Reimbursement notice	boolean true	Purchasers participating in the offer to the public of crypto-asset will be able to be reimbursed if the minimum target subscription goal is not reached at the end of the offer to the public, if they exercise the right to withdrawal provided for in Article 13 of Regulation (EU) 2023/1114 of the European Parliament and of the Council or if the offer is cancelled
E.16 Refund mechanism	textBlock	Refunding may occur in accordance with Art 13 MiCAR or in case the minimum subscription goal is not reached. Following the initial purchase of BIOX a waiting period of 14 days applies. During this waiting period locking-up of BIOX is not possible. BIOX holder may send the refund request by e-mail (A.9) or in writing to the business address (A.3). If the request is submitted on time, a refund will be granted according to the refund mechanism in E.26.
E.17 Refund timeline	text	With reference to E.16 and E.26 the refund will be processed without undue delay and in any event no later than 14 days from the date of the withdrawal declaration.
E.18 Offer phases	textBlock	The public offering for the sale of BIOX started on December 16th 2025 and ends on June 17th 2026. The offeror is entitled to shorten or terminate the offering phase at any time. The total number of BIOX is not limited by number.
E.19 Early purchase discount	textBlock	Not applicable.
E.20 Time-limited offer	boolean	true
E.21 Subscription period beginning	date	2025-12-16
E.22 Subscription period end	date	2026-06-17
E.23 Safeguarding arrangements for offered funds or other tokens	textBlock	To ensure the secure storage of the collected funds during the withdrawal period established under Article 13 MiCAR, the collected funds are held in a bank account with an authorized credit institution. The BIOX holder bears the insolvency risk during this withdrawal period.
E.24 Payment methods for other token purchase	textBlock	BIOX can be purchased via the platform www.biogena.com/biox. The offered payment methods include presumably both bank transfer and instant transfer as well as credit card payments. Payment methods are subject to change.
E.25 Value transfer methods for reimbursement	textBlock	In the event of a timely withdrawal in accordance with E.26, the buyer will receive a refund of the exact amount they invested. The initially amount will be transferred to the same bank account that the initial sum was transferred from. Art 13 MiCAR applies.
E.26 Right of withdrawal	textBlock	In accordance with Article 13 of Regulation (EU) 2023/1114, retail investors who acquire crypto-assets other than asset-referenced tokens and e-money tokens directly from a provider are entitled to a right of withdrawal. Retail investors have a period of 14 calendar days to withdraw their consent to the purchase of crypto-assets other than asset-referenced tokens and electronic money tokens free of charge and without providing any reason. The withdrawal period begins on the day the retail investor gives consent to the purchase of these crypto-assets.
E.27 Transfer of purchased other tokens	textBlock	Upon the acquisition of BIOX, BIOX is transferred to a custodial wallet,. For the BIOX holder the amount of acquired BIOX is visible in the user interface, which the holder can access via his/her account at www.biogena.com/biox. Upon locking-up of BIOX the respective amount of token in the holders custodial wallet is locked by a technical mechanism for the duration of the lock-up period. BIOX can be transferred upon expiry of the withdrawal period and upon implementation of the transferability functionality (D.8).
E.28 Transfer time schedule	text	The transfer of BIOX will take place no later than one (1) day following receipt of the payment by the issuer and valid initial purchase, subject to achievement of the milestone "Transferability functionality" (see D.8).
E.29 Purchaser's technical requirements	textBlock	The purchaser must register at www.biogena.com/biox and create an account. In case of unlocking after the initial locking-up of BIOX a separate Ethereum wallet may be required to transfer gas fees. In case the BIOX holder whishes to trade BIOX publicly an additional account at a reputable trading platform will be require to trade BIOX.
Other token services provider characteristics
E.30 Other token service provider (CASP) name	text	Tangany GmbH
E.31 CASP identifier	LEI	529900WKXS5ZPJY9W498
E.32 Placement form	enumeration	Not applicable
Trading platforms characteristics
E.33 Trading platforms name	text	At the time of the initial token offering (16th of December 2025) trading BIOX on a trading platform is not implemented. It is envisaged to implement this in the future.
E.34 Trading platforms market identifier code (MIC)	text	Not applicable.
E.35 Trading platforms access	text	Not applicable.
E.36 Involved costs	textBlock	Not applicable.
E.37 Offer expenses	textBlock	There are no expenses or costs for the purchaser in relation to the initial public offer other than the purchase price.
E.38 Conflicts of interest	textBlock	Dr. Albert Schmidbauer indirectly holds shares in the company. As a result, regardless of his role as managing director of the managing general partner of the issuer, he has financial and economic interests that may differ from those of the issuer and thus may represent a potential conflict of interest. All managing directors of the issuer's general partner also hold management positions in other companies of the Biogena Group, which may also lead to a potential conflict of interest. In the opinion of the offeror, there are no active conflicts of interest.
E.39 Applicable law	textBlock	Austrian law (unless otherwise governed by applicable international private law).
E.40 Competent court	textBlock	Austrian courts (if not otherwise resulting from applicable international procedure law).
Part F - Information about other tokens
F.1 Crypto-asset type	text	BIOX is classified as a "crypto-asset other than an asset-referenced token or e-money token". BIOX does qualify as a Utility Token pursuant to Art 3 para 1 no 9 of Regulation (EU) 2023/1114.
F.2 Other token functionality	textBlock	BIOX is a token that shall provide access to rebates according to section D.7.
F.3 Planned application of functionalities	textBlock	The rebate function as well as other benefits are effective as soon as BIOX is locked-up by the BIOX holder. After BIOX has been acquired it is not automatically locked-up. It is the users discretion to lock-up BIOX as activation of rebates requires locking-up of the corresponding amount (see 09, D.7, E.14) of BIOX by the BIOX holder. The locking-up period is at least 12 months, to make use of the granted rebates and other benefits. The holder is entitled to the benefits (D.7) immediately after locking-up the required amount of BIOX.
A description of the characteristics of the other token, including the data necessary for classification of the crypto-asset white paper in the register referred to in Article 109 of Regulation (EU) 2023/1114, as specified in accordance with paragraph 8 of that Article
F.4 Type of crypto-asset white paper	enumeration	Other crypto-asset token white paper
F.5 Type of submission	enumeration	Modify
F.6 Other token characteristics	textBlock	BIOX shall be minted as an ERC-20 token (token standard as explained in section D.8). There is no initial amount of token minted. BIOX are minted in the course of acquisitions of BIOX by customers.
F.7 Commercial name or trading name	text	BIOGENA EXPERIENCE TOKEN (ticker: BIOX)
F.8 Website of the issuer	text	www.biogena.com or www.biogena.com/biox
F.9 Starting date of offer to the public or admission to trading	date	2025-12-16
F.10 Publication date	date	2026-03-12
F.11 Any other services provided by the issuer	textBlock	Biogena GmbH & Co KG does not perform any other services regulated under Austrian Law. For Business activities see A.12.
F.12 Language or languages of white paper	text	English
F.13 Digital token identifier code used to uniquely identify the crypto-asset or each of the several crypto assets to which the white paper relates, where available	text	5HL762TWK
F.14 Functionally fungible group digital token identifier, where available	text	Not available.
F.15 Voluntary data flag	boolean	false
F.16 Personal data flag	boolean
F.17 LEI eligibility	boolean	true
F.18 Home member state	enumeration	Austria
F.19 Host member states #1	enumerationSet	Germany
Part G - Information on rights and obligations attached to other tokens
G.1 Purchaser rights and obligations	textBlock	BIOX (BIOGENA EXPERIENCE TOKEN) is an ERC-20 token. It does not convey any claims, shareholder rights, or entitlements, whether contingent or actual, against the offeror, any affiliates, or any other third parties, beyond the token's functionalities as described in this white paper, namely, locking-up. Beyond these utilities, BIOX does not convey any claims or rights, other than ownership rights over the tokens themselves and rebates as set forth in this white paper. BIOX does not grant rights to dividends, interest payments, principal repayments, or corporate voting. Holding BIOX does not create any debt or equity relationship between the holder and the offeror (or its affiliates).
G.2 Exercise of rights and obligations	textBlock	BIOX holders can lock-up their token to unlock the respective level of the Biogena Experience. For avoidance of any doubt, it is only possible to lock-up the required amount of BIOX for each level (see 09, D.7 or E.14) and not a higher or lower amount of BIOX. However, the amount of BIOX purchased and held by the holder remains at the holder's discretion. BIOX holders can lock-up their tokens via their account at www.biogena.com/biox, which offers a frontend interface for locking-up. The corresponding backend for the locking-up procedure is provided by the offeror. By locking-up the required BIOX for each level, the respective rebate will be automatically deducted of the BIOX holders purchase or booking. It is the BIOX holders choice whether BIOX shall be locked-up or unlocked. Following the initial purchase, BIOX is not locked-up automatically.
G.3 Conditions for modifications of rights and obligations	textBlock	Rights and obligations regarding BIOX cannot be amended in the discretion of the offeror. New legislation applicable to the Biogena Experience Token Project, can lead to changes due to compliance with mandatory laws.
G.4 Future public offers	textBlock	No future public offers are planned or envisaged by the offeror as of the date of this white paper.
G.5 Issuer retained other token	integer	35000000
G.6 Utility token classification	boolean	true
G.7 Key features of goods or services utility tokens	text	BIOX shall provide access to rebates for all Biogena micronutrients and food supplements as well as to services provided by the Biogena and more. BIOX shall grant rebates on the following, grant benefits and require a certain number of locked-up BIOX starting by at least 3,000: • rebates of 30% of the purchase price (regular price and promotional or discounted price) on all Biogena products, biohacking applications and wellbeing checks and subscriptions for every single purchase for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and thereof 3,000 BIOX are being locked-up. • participation of the BIOX holder in raffles (Verlosungen) of tickets for at least 300 different cultural and sporting events. The raffles shall take place once a year and shall contain each of about 100 tickets for the "Jedermann"-Festival, Kitzbühel Streif ski event and Skybox VIP invitations for the Red Bull Arena in Salzburg. Further events shall be made available, such as specific Health Days and a yearly dinner with the Founder and Management Team. The raffles shall be conducted for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and thereof 3,000 BIOX are being locked-up. • one free subscription to Biogena ONE, an All-in-ONE green drink, plus ADD+ ONE Omega-3 Support for a maximum period of 40 years (monthly delivery), calculated beginning at the regular end of the offer phase, if and as long as 30,000 or more BIOX are being held and thereof 30,000 BIOX are being locked-up. • initial offer exclusively for token holders and discounts to real estate investments in up to 25 'Welcome to Yourself Resorts (WTY)' planned worldwide, depending on the amount of BIOX held and locked-up as follows: (i) initial offer exclusively for token holders and 10% discount if 30,000 to 99,999 are being held and thereof 30,000 BIOX are being locked-up, (ii) initial offer exclusively for token holders and 20% discount if 100,000 to 199,999 are being held and thereof 100,000 BIOX are being locked-up, (iii) initial offer exclusively for token holders and 25% discount if 200,000 or more BIOX are being held and thereof 200,000 BIOX are being locked-up. For the avoidance of any doubt, the offeror (i) envisages building 'Welcome to Yourself Resorts (WTY)', but shall have no legal obligation to do so and (ii) has not yet decided on the detailed structure of such respective investment. In case the offeror offers an investment opportunity in 'Welcome to Yourself Resorts (WTY)', such offer shall be offered to the holders of BIOX, having held and locked-up 30,000 BIOX or more, at least for a period of fourteen (14) days before such investment is offered to the public. • one Biogena LONGEVITY Stick monthly subscription for 40 years, calculated beginning at the regular end of the offer phase, if 100,000 or more BIOX are being held and thereof 100,000 BIOX are being locked-up. The Biogena LONGEVITY Stick is a new supplement and micronutrient product aiming to help slow aging. • Limited membership in the 3 BIOX Circles (solely consisting of the members of the ONYX Circle, PLATIN Circle, BERNSTEIN Circle, total maximum of 80 people) combined with a unique piece of jewelry limited in number and crafted by an artist as follows: (i) ONYX Circle Membership, limited to 50 members plus one BIOX Onyx ring, if 30,000 to 99,999 are being held and thereof 30,000 BIOX are being locked-up, (ii) PLATIN Circle Membership, limited to 20 members plus one BIOX Platin ring, if 100,000 to 199,999 are being held and thereof 100,000 BIOX are being locked-up and (iii) BERNSTEIN Circle Membership, limited to 10 members plus one BIOX Bernstein ring, if 200,000 or more BIOX are being held and thereof 200,000 BIOX are being locked-up. (These rebates on products and services as well as other benefits are in the following referred to as the "rebate"). Further, to ensure responsible and sustainable use of BIOX and its granted rebates, the following fair use principle applies to all BIOX holders: 1. Personal use BIOX rebates are intended exclusively for the personal use of the BIOX holder and for personal use within the immediate family. The transfer, sale or commercial use of the rebates is not permitted. An exception to this shall apply within the framework of existing business partner relationships with doctors/therapists, where a use within the practice is considered fair use – but not a resale outside of the practice. 2. Reasonable purchasing frequency Rebates may be used within the scope of a normal and reasonable purchasing frequency. The following applies as a guideline: • a maximum of 6 rebated orders per calendar month. Higher frequencies are possible, but must be in a reasonable proportion to personal consumption and must not reflect resale activities. 3. Quantity limits to prevent abuse BIOX rebates may not be used for: • the purchase of unusually large quantities (e.g. stock purchases for resale), • orders that objectively suggest commercial or systematic use. 4. Protection against automated or technical abuse Any form of automated ordering, price manipulation or circumvention of the rules of use will result in the suspension or termination of the rebate entitlement. 5. Monitoring & transparency The issuer is entitled to: • randomly check the use of rebates, • temporarily block them in case of suspected abuse, • permanently withdraw the rebates entitlement in clear cases. The BIOX holder will be informed transparently about all measures. 6. Fairness principle It shall create a system that: • offers all BIOX holders a fair advantage, • does not create any distortion of competition, • protects the long-term value of the BIOX ecosystem. The issuer undertakes to apply this principle in a customer-friendly, proportionate and transparent manner.
G.8 Utility tokens redemption	text	BIOX will provide access to the above mentioned (e.g. 08, G.7) rebates by locking-up the respective amount of BIOX (3,000, 30,000, 100,000 or 200,000). Tokens locked-up do not represent a direct exchange of goods and services but grant solely a discount on a purchase to the BIOX holder. BIOX is not a medium of exchange and is not intended to be used as such. While tokens are locked-up, they remain in the possession of the BIOX holder, and tokens are not transferred to the offeror. In order to get access to such rebates no redemption of BIOX to the offeror is necessary or planned. Depending on the number of BIOX locked-up by a user, the respective rebate will be applied if logged in to www.biogena.com. This does require to be a user of Biogena. The rebate will be applied by Biogena and, thus, will decrease any price of any services or goods or shares, as the case may be. BIOX token are valid for 40 years, calculated beginning at the regular end of the offer phase, and will not decrease in number by making use of the rebates.
G.9 Non-trading request	boolean	true
G.10 Other tokens purchase or sale modalities	text	Not applicable.
G.11 Other tokens transfer restrictions	text	During the lock-up period of 12 months for locked-up BIOX a transfer is not possible. There are no other transfer restrictions for the purchaser, except D.8 ("Automated Transferability functionality").
G.12 Supply adjustment protocols	boolean	true
G.13 Supply adjustment mechanisms	text	Not applicable.
Other token schemes details
G.14 Token value protection schemes	boolean	false
G.15 Token value protection schemes description	textBlock	Not applicable.
G.16 Compensation schemes	boolean	false
G.17 Compensation schemes description	textBlock	Not applicable.
G.18 Applicable law	textBlock	Austrian Law.
G.19 Competent court	textBlock	The general place of jurisdiction for the issuer is the regional court of Salzburg (Landesgericht Salzburg). As long as no mandatory laws lead to the competence of another court the regional court of Salzburg shall be the competent court.
Part H – Information on underlying technology
H.1 Distributed ledger technology (DTL)	text	BIOX is initally issued on Ethereum as an ERC-20 token supporting cross chain functionalities.
H.2 Protocols and technical standards	text	BIOX operates on Ethereum, which provides for a robust base for token minting and locking-up.
H.3 Technology used	textBlock	BIOX is issued as an upgradeable ERC-20 smart contract on the Ethereum Mainnet, which since September 2022 operates under Proof-of-Stake consensus.
H.4 Consensus mechanism	text	Since 15 September 2022, Ethereum relies on a proof-of-stake consensus mechanism. Ethereum's consensus mechanism involves validators creating blocks. A validator is randomly chosen to propose a block, which includes a bundle of transactions. This block is then sent to other nodes and rewarded in Ether (ETH). In case of multiple potential blocks, a fork choice algorithm selects the block with the highest weight of attestations. The proof-of-stake system ensures security by making it economically prohibitive for attackers to control the chain and incentivizing honest behavior through rewards and penalties.
H.5 Incentive mechanisms and applicable fees	text	On Ethereum, transaction security is driven by gas fees, which users pay to compensate miners for validating transactions. Users set a gas limit and gas price for each transaction. The gas limit is the maximum work the transaction can require, while the gas price is the amount of ETH the user is willing to pay per unit of gas. Higher gas prices incentivize miners to prioritize those transactions.
H.6 Use of distributed ledger technology	boolean	true
H.7 DLT functionality description	textBlock	The underlying blockchain technology will be Ethereum. All transactions will be issued, transferred and stored on the Ethereum blockchain.
Other token audit details
H.8 Audit	boolean	false
H.9 Audit outcome	textBlock	Not applicable.
Part I - Information on risks
I.1 Offer-related risks	textBlock	• Custody Risk: Access to BIOX requires an account at www.biogena.com/biox. As BIOX holder holds the token with crypto-asset services providers offering custody services, the BIOX holder could face the risk of such service providers failing to properly execute their instructions with regard to the storage methods, such as hot trading, hot storage, cold storage, and deep cold storage. In addition, BIOX held with a custodian may not be separable in favor of the investor in the event of insolvency of the custodian or a third-party financial intermediary. Finally, the custodians can face risk of cyberattacks. As a result, of all such custody-related events, the investors will face the risk of loss. • Technological risk: The migration of BIOX to other crypto currencies may be subject to technical malfunctions or errors. In the worst-case scenario, these issues could lead to the loss of tokens.
I.2 Issuer-related risks	textBlock	• Risk of Insolvency: Holding BIOX does not entitle the holder to any claim, collateral, or segregation of assets from the offeror. In a hypothetical insolvency, BIOX holders would not have special priority rights. • Business Risk: The offeror's success in micronutrient and longevity markets can indirectly influence the perceived value of BIOX. Downturns, regulatory issues, or decreased user trust could negatively impact any BIOX's secondary market price. • Credit and Counterparty Risk: The offeror relies on various counterparties; high-profile defaults or failures can impact the platform's operations and user confidence, indirectly affecting BIOX demand. • Operational Risk: Technical or process failures could undermine trust in the ecosystem, potentially reducing demand or utility for BIOX. • Third-Party Risk: Many back-office or liquidity-related services rely on external providers. Failures or vulnerabilities at these providers can negatively affect BIOX availability, liquidity, or usage. • Regulatory Risk: The evolving regulatory landscape may impose new constraints on the offeror, which could indirectly affect the value or usability of BIOX.
I.3 Other tokens-related risks	textBlock	• Risk of Loss: Upon implementation of trading BIOX on trading plattforms, BIOX's price can be volatile, and investors could incur substantial losses, including a complete loss of value. • High Volatility & Illiquidity: BIOX is not backed by physical assets or guaranteed returns. Secondary market liquidity can be unpredictable; low liquidity can deteriorate price swings. • Abrupt Market Events: Political, economic, or market-specific incidents (e.g. exchange hacks, macroeconomic shifts) can quickly affect BIOX prices. • Market Abuse Risks: Even under Regulation (EU) 2023/1114, certain manipulative tactics or fraudulent practices can persist in crypto-asset markets, posing volatility and transparency challenges. • Regulatory Risk: Different jurisdictions have different rules on crypto-assets. Changes in law or enforcement actions could disrupt BIOX trading or usage in certain regions. • ESG-Related Risk: Ethereum's (and corresponding EVM-based chains) move to proof-of-stake has reduced energy consumption, but some investors may still view crypto negatively from an ESG standpoint. • Taxation Risk: BIOX transactions may be taxed differently across Member States or non-EU jurisdictions. Regulatory or classification changes can alter tax obligations, potentially impacting investment returns. It is the BIOX holders sole responsibility to be aware of taxation and fiscal treatment of BIOX in accordance with the acquisition and possible trading of BIOX.
I.4 Project implementation-related risks	textBlock	• Risks associated with project implementation: As the issuer is seeking trading admission, risk of delay in the admission processor time line may as well as technical implementation risks may occur. • Risks associated with project implementation: Risks of delay in or failure of the achievement of the milestones (D.8) may apply. Projects implementation risks are not limited to the previously mentioned risks.
I.5 Technology-related risks	textBlock	• Blockchain Vulnerabilities: As a ERC-20 token, BIOX depends on Ethereum's and other compatible blockchain's reliability. Network disruptions, consensus failures, or severe bugs could impair transfers or usage. • Cyber Risks: Attacks targeting private keys, smart contract exploits, or node manipulations could lead to losses or a collapse of user confidence. • Smart Contract Risks: Coding errors or unforeseen vulnerabilities in BIOX's migration/governance contracts could lead to partial or total token loss for certain users. • Consensus Mechanism Attacks: While proof-of-stake is designed to be secure, a 51% attack is theoretically possible if an entity controls a majority stake, potentially invalidating honest transactions. • Irreversibility of Transactions: Once BIOX is transferred on-chain, the transaction is final. Mistakes (e.g. sending to a wrong address) typically cannot be reversed. • Forking Risk: Ethereum or other relevant chains can fork, creating parallel tokens or splitting the chain. This may result in confusion, lost liquidity, or partial devaluation of existing BIOX. • Limited Control: The issuer cannot control global internet routing, user hardware, or external factors that might impair connectivity to the BIOX ecosystem. • Unanticipated Risks: New and evolving technology can reveal unanticipated security issues or usage patterns, leading to additional unforeseen risks.
I.6 Mitigation measures	textBlock	• Due Diligence: The offeror applies rigorous standards for selecting third-party service providers and designs robust internal procedures to safeguard operations. • Liquidity & Volatility Management: The offeror may engage in liquidity measures, buybacks, or promotional campaigns to encourage adoption and manage volatility. The offeror or its subsidiary companies may make use of the amount of BIOX held in respect of any measures as mentioned in the foregoing sentence. • Security Practices: Continual monitoring of potential threats, internal bug bounty programmes, and, where feasible, external audits help mitigate some technology-related risks.
Part J - Information on the sustainability indicators in relation to adverse impact on the climate and other environment-related adverse impacts
J.1 Adverse impacts on climate and other environment-related adverse impacts	textBlock	Information is provided in S.1 ff. S.10 ff are not applicable as the total amount of energy used for the validation of transactions and the maintenance of the integrity of the distributed ledger of transactions, expressed per calendar year does not exceed 500,000 kwh.
Mandatory information on principal adverse impacts on the climate and other environment-related adverse impacts of the consensus mechanism
General information about adverse impacts
S.1 Name	text	Biogena GmbH & Co KG
S.2 Relevant legal entity identifier	text	52990050KC7YUM8VD941
S.3 Name of the crypto-asset	text	Biogena Experience Token (BIOX)
S.4 Consensus mechanism	text	Since 15 September 2022, Ethereum relies on a proof-of-stake consensus mechanism. Ethereum's consensus mechanism involves validators creating blocks. A validator is randomly chosen to propose a block, which includes a bundle of transactions. This block is then sent to other nodes and rewarded in Ether (ETH). In case of multiple potential blocks, a fork choice algorithm selects the block with the highest weight of attestations. The proof-of-stake system ensures security by making it economically prohibitive for attackers to control the chain and incentivizing honest behavior through rewards and penalties.
S.5 Incentive mechanisms and applicable fees	text	On Ethereum and other EVM-compatible blockchains, transaction security is driven by gas fees, which users pay to compensate miners for validating transactions. Users set a gas limit and gas price for each transaction. The gas limit is the maximum work the transaction can require, while the gas price is the amount of ETH or other crypto-assets on EVM-compatible blockchain the user is willing to pay per unit of gas. Higher gas prices incentivize miners to prioritize those transactions.
S.6 Beginning of period to which disclosed information relates	date	2025-12-16
S.7 End of period to which disclosed information relates	date	2026-06-17
Mandatory key indicator
S.8 Energy consumption	energy (kWh)	225,00
Sources and methodologies
S.9 Energy consumption sources and methodologies	textBlock	The calculation is based on the calculation method of the Crypto Carbon Ratings Institute (CCRI). This method takes into account the energy-related portion of network activity, without including additional internal company consumption, thereby enabling transparent, verifiable and comparable reporting in accordance with MiCA and SFDR requirements. According to the CCRI a transaction requires on average for a transaction volume of 1,6 Million Transactions per day an energy consumption of 0,0045 kWh per Token. BIOX expects a yearly transaction volume of maximum 50.000 On-Chain Transactions on the Ethereum-Layer-1. Therefore, an energy consumption of 225,00 kWh/p.a (per year) is expected. Sources used for data of this calculation are carbon-ratings.com and ethereum.org.
Supplementary information on principal adverse impacts on climate and other environment-related adverse impacts of consensus mechanism
Supplementary key indicators
S.10 Renewable energy consumption	percent
S.11 Energy intensity	energy (kWh)
S.12 Scope 1 DLT GHG emissions - controlled	GHG emissions (tCO2e)
S.13 Scope 2 DLT GHG emissions - purchased	GHG emissions (tCO2e)
S.14 GHG intensity	GHG emissions (tCO2e)
Sources and methodologies
S.15 Key energy sources and methodologies	textBlock	n/a see S.10
S.16 Key GHG sources and methodologies	textBlock	n/a see S.10
Optional information on principal adverse impacts on the climate and on other environment-related adverse impacts of the consensus mechanism
Optional indicators
S. 17 Energy mix	percent
S.18 Energy use reduction
Energy use reduction target (absolute value)	energy (kWh)
Energy use reduction target (percentage)	percent
S.19 Carbon intensity (kgCO2e/kWh)	decimal
S.20 Scope 3 DLT GHG emissions - value chain	GHG emissions (tCO2e)
S.21 GHG emissions reduction targets or commitments	textBlock
S.22 Generation of waste electrical and electronic equipment (WEEE)	mass (tonnes)
S.23 Non-recycled WEEE ratio	percent
S.24 Generation of hazardous waste	mass (tonnes)
S.25 Generation of waste (all types)	mass (tonnes)
S.26 Non-recycled waste ratio (all types)	percent
S.27 Waste intensity (all types)	mass (tonnes)
S.28 Waste reduction targets or commitments (all types)	textBlock
S.29 Impact of use of equipment on natural resources	textBlock
S.30 Natural resources use reduction targets or commitments	textBlock
S.31 Water use	volume (m3)
S.32 Non recycled water ratio	percent
Sources and methodologies
S.33 Other energy sources and methodologies	textBlock
S.34 Other GHG sources and methodologies	textBlock
S.35 Waste sources and methodologies	textBlock
S.36 Natural resources sources and methodologies	textBlock